Prism Medico reports net profit of ₹31.84 lakh in FY26
Prism Medico and Pharmacy Limited reported a net profit of ₹31.84 lakh for the financial year ended March 31, 2026, reversing the net loss of ₹4.87 lakh recorded in the previous year. Revenue from operations surged to ₹244.34 lakh in FY26 from ₹63.19 lakh in FY25, driven primarily by the sale of pharmaceutical products. The board approved the audited standalone financial results at its meeting held on May 28, 2026. The statutory auditors, Garg Mendiratta & Associates, issued an unmodified opinion on the financial statements.

*this image is generated using AI for illustrative purposes only.
Prism Medico and Pharmacy Limited reported a net profit of ₹31.84 lakh for the financial year ended March 31, 2026, reversing the net loss of ₹4.87 lakh recorded in the previous year. Revenue from operations surged to ₹244.34 lakh in FY26 from ₹63.19 lakh in FY25, driven primarily by the sale of pharmaceutical products. The board approved the audited standalone financial results at its meeting held on May 28, 2026, at the registered office in Kala Amb, Himachal Pradesh.
Financial Performance
The company’s total income for FY26 stood at ₹246.95 lakh, a significant increase from ₹64.84 lakh in the previous year. Total expenses for the period were ₹203.99 lakh, up from ₹71.42 lakh in FY25. The profit before tax for the year was ₹42.96 lakh, compared to a loss before tax of ₹6.58 lakh in the preceding year. The board reviewed the performance for the quarter and financial year ended March 31, 2026, along with the Auditors Report.
| Metric | FY26 (₹ in Lakhs) | FY25 (₹ in Lakhs) |
|---|---|---|
| Revenue from Operations | 244.34 | 63.19 |
| Total Income | 246.95 | 64.84 |
| Total Expenses | 203.99 | 71.42 |
| Profit Before Tax | 42.96 | (6.58) |
| Net Profit | 31.84 | (4.87) |
Auditor and Compliance Details
The statutory auditors, Garg Mendiratta & Associates, issued an unmodified opinion on the financial statements. The audit report confirms that the company has not incurred any cash losses in the current financial year, compared to a cash loss of ₹6.16 lakh in the preceding year. The board also approved the recommendation of a dividend, if any, subject to the approval of shareholders. The disclosure was made in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Historical Stock Returns for Prism Medico & Pharmacy
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| 0.0% | -3.56% | -6.52% | +43.33% | +86.33% | +223.38% |
What specific strategies drove the nearly fourfold increase in revenue from operations?
Can the company sustain this rapid revenue growth and profitability into FY27?
Will the board recommend a dividend payout given the return to profitability?

































